Bio-Fd&C바이오에프디엔씨
251120 · KOSDAQ · ₩251120 · 바이오에프디엔씨
₩9,140▼ ₩60 (0.65%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩19B | ₩16B | ₩16B | ₩16B | ₩12B |
| Cost of sales | ₩6.3B | ₩4.9B | ₩4.6B | ₩4.9B | ₩4.8B |
| Gross profit | ₩13B | ₩11B | ₩11B | ₩11B | ₩7.1B |
| Operating income | ₩6.3B | ₩4.9B | ₩5B | ₩4.9B | ₩3.1B |
| Net income | ₩6.7B | ₩4.5B | ₩5.6B | ₩4.3B | ₩2.9B |
| Net income to shareholders | ₩6.7B | ₩4.5B | ₩5.6B | ₩4.3B | ₩2.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩73B | ₩67B | ₩63B | ₩59B | ₩23B |
| Current assets | ₩58B | ₩51B | ₩46B | ₩45B | ₩9.2B |
| Cash and equivalents | ₩11B | ₩7.7B | ₩12B | ₩11B | ₩5B |
| Total liabilities | ₩3.7B | ₩4.2B | ₩4.2B | ₩6.1B | ₩7.2B |
| Current liabilities | ₩3.4B | ₩4B | ₩4.1B | ₩6B | ₩6.8B |
| Borrowings | ₩100M | ₩1.2B | ₩1.2B | ₩3.4B | ₩3.8B |
| Total equity | ₩70B | ₩63B | ₩59B | ₩53B | ₩16B |
| Shareholders' equity | ₩70B | ₩63B | ₩59B | ₩53B | ₩16B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩7.3B | ₩6B | ₩6B | ₩5.6B | ₩3.7B |
| Capital spending | ₩974M | ₩1.3B | ₩2B | ₩152M | ₩7B |
| Free cash flow | ₩6.3B | ₩4.8B | ₩4.1B | ₩5.4B | −₩3.3B |
Consolidated where available. Amounts in won.
Also known as: Bio-Fd&C / 바이오에프디엔씨 / 251120 / KRX:251120
Source: KRX statistical information